康华生物 (300841)
Chengdu Kanghua Biological Products Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 12994.69
- Circulating A-Shares(W): 11892.93
- Earnings Per Share(RMB): 1.4553
- Net Assets Per Share(RMB): 26.9854
- Operating Revenue(W RMB): 84006.26
- Total Profit(W RMB): 22165.40
- Net Profit Attributable to Parent(W RMB): 18911.07
- Net Profit Growth Rate(%): -53.41
- Weighted Return on Equity(%): 5.4300
- Operating Cash Flow Per Share(RMB): 1.1830
- Undistributed Profit Per Share(RMB): 18.8404
- Capital Reserve Per Share(RMB): 6.6270
2. Main Business
The main business covers:
- Research, production and sales of human vaccines
3. Company Basic Information
- Company Name: Chengdu Kanghua Biological Products Co., Ltd.
- Listing Date: 2020-06-16
- Industry: Pharmaceutical Manufacturing
- Address: No. 182 Beijing Road, Chengdu Economic and Technological Development Zone, Sichuan Province
- Website: www.kangh.com
- Company Profile: The company was established through the overall change of Kanghua Limited. On July 16, 2018, Kanghua Limited held a shareholders' meeting and resolved that all shareholders of Kanghua Limited, as promoters, would use May 31, 2018 as the reference date to convert the audited net assets of 276,237,006.11 RMB by BDO China Shu Lun Pan Certified Public Accountants LLP at a ratio of 6.1386:1 into 45 million shares of the joint-stock company, thereby establishing a joint-stock company through overall change. On the same day, all shareholders of Kanghua Limited signed the "Sponsor Agreement." On the same day, the joint-stock company (in preparation) held its inaugural meeting and resolved to approve the overall change of Kanghua Limited into a joint-stock company. BDO China Shu Lun Pan Certified Public Accountants LLP issued the "Capital Verification Report" (Xin Hui Shi Bao Zi [2018] No. ZD10153), verifying the capital contribution for the overall change of Kanghua Limited into a joint-stock company. On July 24, 2018, the Chengdu Administration for Industry and Commerce issued the "Business License" to the joint-stock company, with the unified social credit code 91510112758779783Q. After self-inspection by the company and confirmation by the accountants, adjustments were made to the book value of net assets as of May 31, 2018, the restructuring reference date. The related accounting treatments comply with the provisions of the "Accounting Standards for Business Enterprises."
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Aokang Group Co., Ltd. | General Legal Person | 1630.55 | 13.71 |
| 2 | Jinan Kangyue Qiming Investment Partnership (Limited Partnership) | General Legal Person | 941.40 | 7.92 |
| 3 | Sichuan Development Securities Investment Fund Management Co., Ltd. - Sichuan Development Selection No. 3 Private Securities Investment Fund | Private Securities Investment Fund | 807.90 | 6.79 |
| 4 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 118.26 | 0.99 |
| 5 | Southern China Securities 1000 Exchange Traded Open-End Index Securities Investment Fund | Fund | 85.06 | 0.72 |
| 6 | Shanghai Xuanding Private Fund Management Co., Ltd. - Xuanding Rongrui No. 2 Private Securities Investment Fund | Private Securities Investment Fund | 72.52 | 0.61 |
| 7 | National Social Security Fund 114 Portfolio | Social Security Fund | 60.00 | 0.50 |
| 8 | Caitong Asset Management Health Industry Hybrid Securities Investment Fund Class A | Fund | 15.00 | 0.13 |
| 9 | Caitong Asset Management Innovative Medicine Hybrid Securities Investment Fund Class A | Fund | 4.00 | 0.03 |
| 10 | ChinaAMC ChiNext Mid-Cap 200 Exchange Traded Open-End Index Securities Investment Fund Initiating Linked Fund Class A | Fund | 0.01 | 0.00 |
5. Concept Sectors
- Biological Vaccine
- Synthetic Biology
- Margin Trading & Securities Lending
- High-Performance Stock
- MSCI Constituent
- Control Change
- Private Placement Heavy Holdings
- ChiNext 300
- ChiNext Medicine
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information